BCEIA 2023 ‖ 大会报告特邀专家——Prof. Jeremy K Nicholson

2023-08-16 14:20:52 81阅读次数

扫码分享

Prof. Jeremy K Nicholson

Murdoch University and Imperial College London

报告题目：Molecular Spectroscopy in Precision Medicine

报告摘要

Phenomics is the systematic study of the continuum of gene-environment interactions throughout life and the measurement of the emergent physical and chemical properties that result from these interactions and define individual and population phenotypes in health and disease. In molecular phenomics we are concerned with the chemical and biochemical signatures (metabolites, proteins, transcripts etc. of cells and biofluids and how these change in characteristic ways during the onset, development, and recovery from disease. Advanced technologies such as LC-MS and NMR spectroscopy provide convenient multivariate signatures for a wide variety of metabolites and are a rich source of molecular phenomic data. I will illustrate the integrative use of multiple phenomic technologies for studying the COVID-19 patient journey using collections of samples from multiple populations round the world and demonstrate a translational analytical strategy for population level monitoring and assessment of Long COVID and functional biochemical recovery from the disease together with new diagnostic models and markers for clinical deployment. The analytical and informatic strategies developed and employed here are also suitable to help in future pandemic preparedness in world that is likely to be dominated by novel emergent zoonotic threats for decades to come.

个人简介

A pioneer in biological NMR spectroscopy, metabolic phenotyping and precision systems medicine, Nicholson’s major research focus is on the development of diagnostic and prognostic molecular phenotyping technologies as applied to personalised healthcare, metabolic disease, and population phenotyping. Professor Nicholson obtained his PhD from King’s College London in 1980. After a series of academic appointments in Pharmacology and Chemistry at Birkbeck and University College London, he was made full Professor of Biological Chemistry in 1992. He was appointed as Professor and Head of Biological Chemistry at Imperial College London in 1998, Head the Department of Surgery and Cancer (2009-2018), Director for the Centre for Gut and Digestive Health, and Director of the MRC-NIHR National Phenome Centre (2012-2018), Emeritus Professor (2018-to date). He became the Pro-Vice Chancellor for Health Sciences at Murdoch University and Director of the Australian National Phenome Centre in Perth, Western Australia in 2019. Since 2020 he has been leading an international group working on the metabolic sequelae and long-term complications of COVID-19. He is a “Highly-Cited” Researcher in Pharmacology and Toxicology and Cross-Field Science 2013-2023 (Clarivate H index = 141, Google H = 164, 116K citations) and has received various research prizes including: The Royal Society of Chemistry (RSC) Silver (1992) and Gold (1997) Medals for Analytical Science and Analytical Chemistry; The UK Chromatographic Society Jubilee Silver Medal (1994); Pfizer International Prize for Chemical and Medicinal Technology (2002); RSC medal for Chemical Biology (2003); RSC Interdisciplinary Prize (2008); Pfizer Global Research Prize for Chemistry (2006) and the Semmelweis-Budapest Prize for Biomedicine (2010). He holds multiple visiting, and Honorary Professorships including Fudan University, Shanghai, The Mayo Clinic, University of New South Wales, Khon Kaen University, Thailand, Shanghai Jiao Tong University, Zhejiang University, University of Western Australia, Chinese Academy of Sciences, Wuhan, and Dalian. He was elected, Fellow of The UK Academy of Medical Sciences in 2010; Honorary Lifetime Fellow of the International Metabolomics Society in 2012; Honorary Lifetime Member of the US Society of Toxicology in 2013; Albert Einstein Honorary Professor of the Chinese Academy of Sciences in 2014; Elected Honorary Fellow of the Royal College of Physicians (London, 2018); Honorary Doctor of Science, Honoris Causa (Hong Kong Baptist University, 2020). His research group currently specialises in the discovery and development of immuno-metabolic models of inflammatory diseases and their translational application in the clinic.